Gulden Celik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gulden Celik has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Mert Ahmet Kuşkucu
Koç University-İşbank Center for Infectious Diseases (KUISCID), Topkapi, İstanbul, Türkiye; Koç University, School of Medicine, Medical Microbiology, Rumelifeneri Yolu, Sariyer, İstanbul, Türkiye
2 shared publications - Rabia Can Sarınoğlu
Yeditepe Üniversitesi Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, İstanbul, Türkiye
2 shared publications - Seyhan Ordekci
Acıbadem Atakent Hastanesi, Tıbbi Mikrobiyoloji Kliniği, İstanbul
2 shared publications - Arzu İlKi̇
Faculty of Medicine, Department of Medical Microbiology, Marmara University , İstanbul, Turkey
1 shared publication - Aydan Karagül
Antalya Eğitim ve Araştırma Hastanesi, Tıbbi Mikrobiyoloji ve Tıbbi Viroloji Kliniği, Antalya
1 shared publication - Aylin Erman Daloğlu
Department of Medical Microbiology, Antalya Education and Research Hospital, Antalya, Türkiye
1 shared publication
Latest Publications
- 23 October 2025
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 59 (4) , 475-491
HIV Enfeksiyonu Tanı Verilerinin Üç yıllık Çok Merkezli Analizi
Türkiye'de kullanılan üç basamaklı insan immün yetmezlik virüsü [human immunodeficiency virus (HIV)] testi algoritması, Centers for Disease Control and Prevention güncel HIV testi algoritmasına uygun olarak 2019 yılında güncellenmiş ve yürürlüğe girmiştir. Bu çalışmada, HIV/edinilmiş bağışıklık yetmezliği sendromu tanısında ülkemizdeki mevcut durumun ortaya konması amacıyla çok merkezli ve multidisipliner bir yaklaşımla HIV test verileri hakkında çok merkezli veri elde edilebilmesi ve HIV tanısında yeni algoritma uygulamaları ve sahada yaşanılan problemlerin tespit edilebilmesi amaçlanmıştır. Bu amaçla 12 HIV test merkezine 57 soruluk bir anketle kullandıkları HIV test algoritmaları, uygulamada karşılaştıkları sorunlar ve çözüm önerileri sorulmuştur. 2018-2020 yılları arasındaki toplam üç yıllık dördüncü kuşak HIV enzim bağlantılı immünosorbent testi [enzyme linked immunsorbent assay (ELISA)] test sayıları, tekrarlayan reaktif test sayıları, HIV doğrulama test sonuçlarının dağılımı ve HIV nükleik asit amplifikasyon test (NAT) sayıları ile mevcut algoritmanın performansı ve merkezlerin güncel HIV durumu değerlendirilmiştir. 2018-2020 yılları arasında toplam çalışılan anti-HIV ELISA test sayıları yıllara göre sırasıyla 788261, 871299, 835498, tekrarlayan reaktivite oranları 0.48, 0.51 ve 0.70 iken; doğrulanmış HIV test oranları ise 0.24, 0.25 ve 0.21 olarak bulunmuştur. Bu dönemde Western Blot (WB) doğrulama testi kullanım oranları sırasıyla %25.77, %12.29 ve %9.86 olup kullanımının giderek azaldığı görülmektedir. Mevcut algoritmada önerilen HIV-1/2 antikor ayırt edici hızlı doğrulama testlerinin (AAEHDT) kullanım oranları sırasıyla %25.72, %38.76 ve %45.78 olarak bulunmuş olup WB'nin yerini aldığı görülmektedir. Yıllara göre çalışılan HIV-1 RNA oranları da sırasıyla %48.77, %97.98 ve %46.31 olarak bulunmuştur. Çalışmada yeni algoritmada yer alan HIV-1/2 antikor ayırt edici hızlı doğrulama testinin kullanımının giderek arttığı ve HIV tanısında daha etkin kullanıldığı, HIV-1 NAT kullanımının ise azaldığı görülmektedir. Koronavirüs hastalığı 2019 [coronavirus diseases-2019 (COVID-19)] pandemisinin gölgesinde NAT olanaklarının COVID-19 polimeraz zincir reaksiyonu çalışmalarına kaydırılmasıyla ilişkilendirilen bu durum, ülkemizdeki HIV salgınındaki olası değişimler açısından daha detaylı izlem gerektirmektedir.
- 23 October 2025
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 59 (4) , 475-491
HIV Enfeksiyonu Tanı Verilerinin Üç yıllık Çok Merkezli Analizi
Türkiye'de kullanılan üç basamaklı insan immün yetmezlik virüsü [human immunodeficiency virus (HIV)] testi algoritması, Centers for Disease Control and Prevention güncel HIV testi algoritmasına uygun olarak 2019 yılında güncellenmiş ve yürürlüğe girmiştir. Bu çalışmada, HIV/edinilmiş bağışıklık yetmezliği sendromu tanısında ülkemizdeki mevcut durumun ortaya konması amacıyla çok merkezli ve multidisipliner bir yaklaşımla HIV test verileri hakkında çok merkezli veri elde edilebilmesi ve HIV tanısında yeni algoritma uygulamaları ve sahada yaşanılan problemlerin tespit edilebilmesi amaçlanmıştır. Bu amaçla 12 HIV test merkezine 57 soruluk bir anketle kullandıkları HIV test algoritmaları, uygulamada karşılaştıkları sorunlar ve çözüm önerileri sorulmuştur. 2018-2020 yılları arasındaki toplam üç yıllık dördüncü kuşak HIV enzim bağlantılı immünosorbent testi [enzyme linked immunsorbent assay (ELISA)] test sayıları, tekrarlayan reaktif test sayıları, HIV doğrulama test sonuçlarının dağılımı ve HIV nükleik asit amplifikasyon test (NAT) sayıları ile mevcut algoritmanın performansı ve merkezlerin güncel HIV durumu değerlendirilmiştir. 2018-2020 yılları arasında toplam çalışılan anti-HIV ELISA test sayıları yıllara göre sırasıyla 788261, 871299, 835498, tekrarlayan reaktivite oranları 0.48, 0.51 ve 0.70 iken; doğrulanmış HIV test oranları ise 0.24, 0.25 ve 0.21 olarak bulunmuştur. Bu dönemde Western Blot (WB) doğrulama testi kullanım oranları sırasıyla %25.77, %12.29 ve %9.86 olup kullanımının giderek azaldığı görülmektedir. Mevcut algoritmada önerilen HIV-1/2 antikor ayırt edici hızlı doğrulama testlerinin (AAEHDT) kullanım oranları sırasıyla %25.72, %38.76 ve %45.78 olarak bulunmuş olup WB'nin yerini aldığı görülmektedir. Yıllara göre çalışılan HIV-1 RNA oranları da sırasıyla %48.77, %97.98 ve %46.31 olarak bulunmuştur. Çalışmada yeni algoritmada yer alan HIV-1/2 antikor ayırt edici hızlı doğrulama testinin kullanımının giderek arttığı ve HIV tanısında daha etkin kullanıldığı, HIV-1 NAT kullanımının ise azaldığı görülmektedir. Koronavirüs hastalığı 2019 [coronavirus diseases-2019 (COVID-19)] pandemisinin gölgesinde NAT olanaklarının COVID-19 polimeraz zincir reaksiyonu çalışmalarına kaydırılmasıyla ilişkilendirilen bu durum, ülkemizdeki HIV salgınındaki olası değişimler açısından daha detaylı izlem gerektirmektedir.
- Open Access
One-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test
Numerous vaccines have been generated to decrease the morbidity and mortality of COVID-19. This study aims to evaluate the immunogenicity of the heterologous boosts by BioNTech against homologous boosts by CoronaVac at three-month intervals in two health care worker (HCW) cohorts, with or without prior COVID-19, for one year post-vaccination. This is a prospective cohort study in which the humoral responses of 386 HCWs were followed-up longitudinally in six main groups according to their previous COVID-19 exposure and vaccination status. Anti-SARS-CoV-2 spike-RBD total antibody levels were measured and SARS-CoV-2 neutralization antibody (NAbs) responses against the ancestral Wuhan and the Omicron variant were evaluated comparatively using international standard serum for Wuhan and Omicron, as well as with the aid of a conversion tool. The anti-SARS-CoV-2 spike-RBD total Ab and Nab difference between with and without prior COVID-19, three months after two-dose primary vaccination with CoronaVac, was statistically significant (p = 0.001). In the subsequent follow-ups, this difference was not observed between the groups. Those previously infected (PI) and non-previously infected (NPI) groups receiving BioNTech as the third dose had higher anti-SARS-CoV-2 spike total Ab levels (14.2-fold and 17.4-fold, respectively, p = 0.001) and Nab responses (against Wuhan and Omicron) than those receiving CoronaVac. Ab responses after booster vaccination decreased significantly in all groups at the ninth-month follow-up (p < 0.05); however, Abs were still higher in all booster received groups than that in the primary vaccination. Abs were above the protective level at the twelfth-month measurement in the entire of the second BioNTech received group as the fourth dose of vaccination. In the one-year follow-up period, the increased incidence of COVID-19 in the groups vaccinated with two or three doses of CoronaVac compared with the groups vaccinated with BioNTech as a booster suggested that continuing the heterologous CoronaVac/BioNTech vaccination, revised according to current SARS-CoV-2 variants and with at least a six-month interval booster would be an effective and safe strategy for protection against COVID-19, particularly in health care workers.
Open AccessOne-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test
Numerous vaccines have been generated to decrease the morbidity and mortality of COVID-19. This study aims to evaluate the immunogenicity of the heterologous boosts by BioNTech against homologous boosts by CoronaVac at three-month intervals in two health care worker (HCW) cohorts, with or without prior COVID-19, for one year post-vaccination. This is a prospective cohort study in which the humoral responses of 386 HCWs were followed-up longitudinally in six main groups according to their previous COVID-19 exposure and vaccination status. Anti-SARS-CoV-2 spike-RBD total antibody levels were measured and SARS-CoV-2 neutralization antibody (NAbs) responses against the ancestral Wuhan and the Omicron variant were evaluated comparatively using international standard serum for Wuhan and Omicron, as well as with the aid of a conversion tool. The anti-SARS-CoV-2 spike-RBD total Ab and Nab difference between with and without prior COVID-19, three months after two-dose primary vaccination with CoronaVac, was statistically significant (p = 0.001). In the subsequent follow-ups, this difference was not observed between the groups. Those previously infected (PI) and non-previously infected (NPI) groups receiving BioNTech as the third dose had higher anti-SARS-CoV-2 spike total Ab levels (14.2-fold and 17.4-fold, respectively, p = 0.001) and Nab responses (against Wuhan and Omicron) than those receiving CoronaVac. Ab responses after booster vaccination decreased significantly in all groups at the ninth-month follow-up (p < 0.05); however, Abs were still higher in all booster received groups than that in the primary vaccination. Abs were above the protective level at the twelfth-month measurement in the entire of the second BioNTech received group as the fourth dose of vaccination. In the one-year follow-up period, the increased incidence of COVID-19 in the groups vaccinated with two or three doses of CoronaVac compared with the groups vaccinated with BioNTech as a booster suggested that continuing the heterologous CoronaVac/BioNTech vaccination, revised according to current SARS-CoV-2 variants and with at least a six-month interval booster would be an effective and safe strategy for protection against COVID-19, particularly in health care workers.
- Open Access
- 4 November 2020
- Published by Wiley in International Journal of Microbiology
- Vol. 2020, 1-5
Antibiotic Resistance Results of Helicobacter pylori in a University Hospital: Comparison of the Hybridization Test and Real-Time Polymerase Chain Reaction
Aim. H. pylori is a bacterial pathogen in the human stomach which infects about 50 of the world population. Untreated infection can lead to various diseases leading to cancer. Some of the H. pylori strains are asymptomatic, but some of them cause more severe diseases. Standard treatment protocol used for the treatment of H. pylori infection is triple therapy, which includes omeprazole as a proton pump inhibitor (PPI) and two antibiotics usually consist of amoxicillin and clarithromycin or metronidazole. In the recent years, because of the increase in the rate of antibiotic resistance, the eradication rate has decreased. Materials and Methods. We evaluated 140 patients who applied to a university hospital gastroenterology department and underwent biopsy during endoscopy. In these patients, we analysed floroquinolone and clarithromycin resistance using the GenoType® HelicoDR (Hain Life Science, Germany). We also used the real-time method for clarithromycin resistance. Results. We found the number and rate of floroquinolone resistance as 20 (25.6) and clarithromycine resistance as 31 (39.7). With the real-time PCR method, we detected clarithromycine resistance in 26 (33.3) patients. These results were not statistically significant. Discussion and Conclusion. Our results show similarity to the other studies held in our country. There should be more studies for the policy of eradication through our country.
- 4 November 2020
- Published by Wiley in International Journal of Microbiology
- Vol. 2020, 1-5
Open AccessAntibiotic Resistance Results of Helicobacter pylori in a University Hospital: Comparison of the Hybridization Test and Real-Time Polymerase Chain Reaction
Aim. H. pylori is a bacterial pathogen in the human stomach which infects about 50 of the world population. Untreated infection can lead to various diseases leading to cancer. Some of the H. pylori strains are asymptomatic, but some of them cause more severe diseases. Standard treatment protocol used for the treatment of H. pylori infection is triple therapy, which includes omeprazole as a proton pump inhibitor (PPI) and two antibiotics usually consist of amoxicillin and clarithromycin or metronidazole. In the recent years, because of the increase in the rate of antibiotic resistance, the eradication rate has decreased. Materials and Methods. We evaluated 140 patients who applied to a university hospital gastroenterology department and underwent biopsy during endoscopy. In these patients, we analysed floroquinolone and clarithromycin resistance using the GenoType® HelicoDR (Hain Life Science, Germany). We also used the real-time method for clarithromycin resistance. Results. We found the number and rate of floroquinolone resistance as 20 (25.6) and clarithromycine resistance as 31 (39.7). With the real-time PCR method, we detected clarithromycine resistance in 26 (33.3) patients. These results were not statistically significant. Discussion and Conclusion. Our results show similarity to the other studies held in our country. There should be more studies for the policy of eradication through our country.